TrovaGene (NASDAQ:TROV) and I-Mab (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, analyst recommendations and institutional ownership.
Valuation & Earnings
This table compares TrovaGene and I-Mab’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
TrovaGene has higher revenue and earnings than I-Mab. TrovaGene is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent recommendations and price targets for TrovaGene and I-Mab, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TrovaGene presently has a consensus target price of $5.50, indicating a potential downside of 61.24%. I-Mab has a consensus target price of $48.00, indicating a potential upside of 57.48%. Given I-Mab’s higher possible upside, analysts clearly believe I-Mab is more favorable than TrovaGene.
Institutional and Insider Ownership
10.0% of TrovaGene shares are owned by institutional investors. Comparatively, 64.4% of I-Mab shares are owned by institutional investors. 0.6% of TrovaGene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares TrovaGene and I-Mab’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
I-Mab beats TrovaGene on 7 of the 11 factors compared between the two stocks.
TrovaGene Company Profile
Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.
I-Mab Company Profile
Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies for cancer treatment. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.